'For­ward, faster' and 200 jobs lighter as fi­bro­sis and kid­ney dis­ease get cut, Gala­pa­gos CEO Stof­fels once again spot­lights deals

New Gala­pa­gos CEO Paul Stof­fels — best known for his turn as the long­time CSO at J&J — has come up with a three-pronged strat­e­gy to dig a way out of the big hole the biotech finds it­self in. And it calls for tak­ing out the bud­get axe and giv­ing the staff 200 whacks so they can put more mon­ey in­to deals.

“Our new fit-for-pur­pose or­ga­ni­za­tion­al struc­ture and op­er­at­ing mod­el will fo­cus on ac­cel­er­at­ing our pipeline in im­munol­o­gy and on­col­o­gy, sup­port­ed by ex­ter­nal­ly sourced op­por­tu­ni­ties, and we will dis­con­tin­ue our ac­tiv­i­ties in fi­bro­sis and kid­ney dis­ease,” Stof­fels not­ed in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER